Theralase Technologies Inc Stock Price, News & Analysis

Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF) has made a significant breakthrough in cancer treatment. Their lead drug formulation, Rutherrin, can now be activated by Metformin, a common diabetes drug, without the need for light or radiation. This discovery allows for precise targeting of cancer cells anywhere in the body, including the brain.

Key findings include:

• Rutherrin combined with Metformin significantly increases Reactive Oxygen Species (ROS) production in Non-Small Cell Lung Cancer (NSCLC) cells
• The combination is even more effective when activated by radiation
• This new method could enable out-patient or in-home cancer treatments
• It potentially reduces treatment costs and burden on patients with mobility

Theralase plans to commence clinical studies for various cancers, pending regulatory approval.

Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF) has released its 2Q2024 financial statements. Key highlights include:

- Total revenue decreased 35% year-over-year

- Gross margin decreased to 33% from 47% in 2023

- Net loss reduced by 6% to $2,400,461

- The company closed three non-brokered private placements, raising approximately $2.7 million

- 72 patients have been enrolled and treated in Study II for BCG-Unresponsive NMIBC CIS

- 63% of treated patients achieved Complete Response (CR)

- 44% of CR patients maintained response for at least 12 months

- The company plans to submit for FDA Break Through Designation in 3Q2024

Theralase aims to complete Study II enrollment by end of 2024 and seeks FDA and Health Canada approval by the end of 2026.

Theralase Technologies, a clinical stage pharmaceutical company, has successfully closed the first tranche of its Non-Brokered Private Placement (NBPP) offering. The company raised $CAN 775,000 by issuing 3,522,729 units at $CAN 0.22 per unit. Each unit includes one common share and one common share purchase warrant, allowing holders to acquire additional shares at $CAN 0.30 each for five years. Funds will support the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study, preclinical research of Rutherrin®, and general corporate purposes. The securities are under a four-month hold and await final acceptance from the TSX Venture Exchange.

Theralase Technologies announced that its lead drug, Rutherrin, has shown promise in repurposing non-cancer drugs for cancer therapy in preclinical research. Rutherrin enhances the efficacy of existing drugs, such as Withaferin A, Amiodarone, and Metformin, in destroying cancer cells. This approach leverages already approved drugs, potentially reducing development costs and timelines. Dr. Arkady Mandel, the Chief Scientific Officer, highlighted the shared molecular pathways between different diseases as a rationale for this repurposing strategy. President Roger DuMoulin-White emphasized the high costs and long timelines of new drug development, underscoring the benefits of repurposing existing drugs for cancer treatment.

Theralase Technologies announced that its lead drug formulation, Rutherrin®, demonstrated a complete response in preclinical studies for Non-Small Cell Lung Cancer (NSCLC). Using a well-established Lewis Lung Cancer (LLC1) model, mice treated with x-ray activated Rutherrin® showed a significant reduction in tumor progression and increased overall survival compared to the control group treated with radiation only. Notably, one mouse achieved a complete response, becoming cancer-free. The company aims to optimize this therapy for higher success rates and expand its cancer treatment targets, which now include bladder, brain, lung, and various blood-based cancers. Pending further research and sufficient funding, Theralase plans to commence clinical studies for these cancers.

Theralase Technologies announced preclinical research revealing that their lead drug, Rutherrin, enhances the efficacy of immunotherapy for cancer treatment. Rutherrin works by killing cancer cells directly and reducing the expression of PD-L1 checkpoint proteins, thus increasing the effectiveness of immunotherapeutic drugs. This combined approach potentially reduces the number of treatments needed and associated side effects. The research was conducted on Non-Muscle Invasive Bladder Cancer (NMIBC) and Glioblastoma Multiforme (GBM) cells, showing significant PD-L1 expression reduction. Additionally, Rutherrin combined with x-ray radiation increased calreticulin expression, an immune system activator, suggesting higher cancer cell destruction rates. Theralase aims to leverage these findings for better cancer treatment outcomes.

Theralase has announced a reminder notice for its Annual General and Special Meeting (AGSM) on June 19, 2024, at 4:30 pm ET, located at 41 Hollinger Road, Toronto, Ontario. The company, focusing on light and radiation-activated therapies for cancer, bacteria, and viruses, will also host a virtual Zoom presentation from 5:30 to 6:30 pm ET, including a corporate presentation and a Q&A session. Shareholders can join via Zoom or conference call, with the session archived on the company's website.

Theralase Technologies has announced promising preclinical results for its lead drug, Rutherrin, which increases the efficacy of chemotherapy while combating multidrug resistance (MDR) in cancer cells. MDR often limits the effectiveness of cancer treatments as cancer cells expel drugs before they can be effective. Rutherrin inhibits this drug expulsion, leading to higher drug retention and increased cancer cell kill rates. The research used various chemotherapeutic drugs and demonstrated significant improvements in drug retention and cancer cell mortality in vitro and in animal models. These findings suggest Rutherrin could significantly enhance current cancer treatments by overcoming MDR, reducing adverse effects, and improving patient outcomes.

Theralase Technologies has announced promising preclinical results for its lead compound, RuvidarTM, when combined with Bacillus Calmette-Guérin (BCG) to form RuBCG. The new compound significantly enhances the efficacy of BCG in killing bladder cancer cells by reversing the negative charge of BCG, allowing better adhesion to cancer cells. In experiments, RuBCG increased cancer cell kill rates and decreased immune checkpoint inhibitor PD-L1 levels. The results suggest RuBCG could offer a more effective treatment for Non-Muscle Invasive Bladder Cancer (NMIBC), potentially overcoming the limitations of BCG alone.